Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
Supreme Court Blocks 5th Circuit Ruling on Abortion Pill Access 
RFK Jr. Spokesman Resigns Over Trump Administration’s Flavored E-Cigarette Policy 
Apple Challenges India Antitrust Probe, Says CCI Copied Rivals’ Claims in App Store Case 
NIH Infectious Disease Leadership Shake-Up Raises Concerns Amid Ebola, Hantavirus Outbreaks 
The government is ‘doubling down’ on its social media ban. But bigger penalties for platforms aren’t enough 
France Keeps Top Health Alert as Officials Brace for Another Heatwave 
DOE Declares Power Grid Emergency as Extreme Heat Strains PJM Electricity Supply 
NRC Proposes Radiation Rule Changes to Boost U.S. Nuclear Power Expansion Under Trump 
Trump Suspends Some Morocco Fertilizer Tariffs to Ease U.S. Supply Shortage 
UK Sanctions 24 Russian-Linked Targets Over Cyberattacks and Election Interference 
Brazil to Phase Out Gasoline Subsidy First as Diesel Support Stays Longer 
Vietnam’s population hit the 100 million milestone. Where’s it headed? 
HHS Watchdog Reports $5.56 Billion in Healthcare Fraud Recoveries as Enforcement Actions Decline 
US Appeals Court Limits ICE Detention Without Bond Hearings After 90 Days 
Trump Administration to Launch Voluntary AI Standards for Frontier Models 
Agios Pharmaceuticals has announced a major regulatory milestone with the U.S. Food and Drug Administration approving mitapivat for the treatment of anemia in adults with alpha- or beta-thalassemia. The approval represents a significant advancement for patients living with these inherited blood disorders, many of whom face lifelong complications related to chronic anemia and frequent blood transfusions.
Mitapivat, an oral therapy developed by Agios, is designed to address the underlying metabolic pathways involved in red blood cell function. The FDA’s decision was supported by strong data from Phase 3 clinical trials, which demonstrated that the treatment significantly improved hemoglobin levels in adult patients with alpha- or beta-thalassemia. In addition to increasing hemoglobin, the trials showed a meaningful reduction in transfusion burden, an outcome that could greatly improve quality of life for patients who currently depend on regular transfusions.
According to the company, mitapivat is expected to become available to eligible patients in late January 2026. This timeline reflects the need to implement a Risk Evaluation and Mitigation Strategy (REMS) program, a requirement set by the FDA to ensure the safe use of the medication. REMS programs are typically mandated when specific safety risks need to be carefully managed through monitoring, education, or controlled distribution.
While the overall clinical trial results were positive, Agios also disclosed safety findings observed during development. Five patients participating in the trials experienced adverse reactions that suggested hepatocellular injury. These cases were closely evaluated and factored into the FDA’s benefit-risk assessment, ultimately leading to the approval with additional safety oversight through the REMS program.
The FDA approval of mitapivat marks an important step forward in the treatment landscape for thalassemia-related anemia. As the first therapy of its kind approved for both alpha- and beta-thalassemia in adults, mitapivat offers new hope for reducing disease burden and improving long-term outcomes. With its upcoming launch and safety measures in place, the therapy is poised to play a key role in addressing unmet needs within the thalassemia community.
